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ABSTRACT
Introduction In breast surgeries, prophylactic antibiotics 
given before the surgical incision as per Joint Commission 
Surgical Care Improvement Project guidelines have been 
shown to decrease the rate of postoperative infections. 
There is, however, no clear consensus on postoperative 
antibiotic prophylaxis in patients undergoing mastectomy 
with indwelling drains. This trial protocol proposes to 
study the difference in rates of surgical site infection (SSI) 
with or without continuation of postoperative antibiotics 
in patients undergoing mastectomy without immediate 
reconstruction and with indwelling drains.
Methods and analysis In this multicentre, double- 
blinded clinical trial, all patients undergoing mastectomy 
(without immediate reconstruction) will receive a 
single prophylactic dose of preoperative antibiotics at 
induction of anaesthesia and will then get randomised 
to either continue antibiotic prophylaxis or a placebo 
postoperatively, for the duration of indwelling drains. The 
primary and secondary outcomes will be development 
of an SSI and antibiotic- associated adverse effects, 
respectively. Data will be collected through a standard 
questionnaire by wound assessors. Intention- to- treat 
analysis will be carried out using STATA V.12. For 
categorical variables, frequencies and percentages will be 
assessed by χ2 test/Fisher’s exact test as appropriate. The 
quantitative variables will be computed by their mean±SD 
or median (IQR) and will be assessed by independent t- 
test/Mann- Whitney test as appropriate. Unadjusted and 
adjusted relative risk with their 95% CI will be reported 
using Cox proportional regression. A p value of <0.05 will 
be considered statistically significant.
Ethics and dissemination Ethical approval has been 
obtained from each site’s Ethical Review Board. The 
study background and procedure will be explained to the 
study participants and informed consent will be obtained. 
Participation in the study is voluntary. All data will be 
deidentified and kept confidential. The study findings will 
be published in scientific media and authorship guidelines 
of International Committee of Medical Journal Editors will 
be followed.




Worldwide, breast cancer comprises 10.4% 
of all cancer among women, making it the 
second most common cancer (after lung 
cancer) and the fifth most common cause 
Strengths and limitations of this study
 ► A pragmatic, multicentre, double- blinded, ran-
domised control trial conducted at public and private 
tertiary care hospitals.
 ► Patients with comorbidities will not be excluded un-
less there is an absolute need for antibiotics postop-
eratively, thus results will be generalisable.
 ► Patients in this study are randomised using the 
block- randomisation technique due to which treat-
ment groups are equal in size and are uniformly dis-
tributed as related to patient characteristics.
 ► The trial excludes patients undergoing immediate 
reconstruction as this procedure is not a commomly 
performed procedure in the developing world.
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of cancer death. In Pakistan, breast cancer is the most 
common malignancy in women, accounting for approx-
imately 40% of all malignant tumours. A study from 
Pakistan conducted at a tertiary care hospital reported 
that regardless of age, the majority of patients in their 
cohort presented with higher stage breast cancer than 
the comparison group of patients in the National 
Cancer Database, which is a hospital registry US data-
base of over 1500 cancer centres.1 The higher stage 
at presentation often leads to a greater likelihood of 
warranting a mastectomy rather than breast conserva-
tion surgery.
Reports of surgical site infections (SSIs) after breast 
surgery may range from 1% to 26%,2–5 which is high 
for surgeries that are considered ‘clean procedures’, as 
defined by the Centers for Disease Control and Preven-
tion (CDC) wound classification system. There is no clear 
consensus on the duration of prophylactic antibiotics in 
patients undergoing mastectomy, and practices may vary 
among breast and reconstructive surgeons. Prophylactic 
antibiotics given before surgical incision/procedures 
as per Joint Commission Surgical Care Improvement 
Project guidelines have been shown to decrease the rate 
of postoperative infections in a vast number of patients. 
However, the efficacy of prophylactic antibiotics used 
after surgeries is not known.6–9 Therefore, most guide-
lines recommend a single dose of periprocedural anti-
biotics, and prolonged continuation after surgery has 
been discouraged. The use of common or more specific 
antibiotics for the duration of drains being in place is 
controversial.
The drains used following breast surgeries are closed 
suction, and they are retained for a variable duration 
depending on the volume of effluent. The likelihood of 
microorganisms contaminating these drains increases 
with longer presence and may result in SSI, yielding 
the same organisms as found in the drains.4 9 Evidence 
regarding the risk of SSI with the use and duration of 
indwelling drains is controversial.4 9–15 Surgical drains are 
commonly removed when output is less than 30 mL/24 
hours, often 5–7 days later; however, some patients can 
have drains in place for weeks before meeting the criteria 
for removal.16
Recent national/international clinical guidelines 
recommend the use of a single dose of preprocedural 
antibiotics for mastectomy patients with or without 
drains.17 18 The American Society of Breast Surgeons also 
does not recommend the continuation of postsurgical 
antibiotics in the absence of relevant indicators, such as 
purulent drainage from the incision or drain site, tender-
ness, localised swelling, erythema or warmth, and clinical 
diagnosis of cellulitis.19 Even in the setting of immediate 
breast reconstruction following mastectomy, there is 
insufficient evidence for the use of extended prophylactic 
antibiotics to reduce SSI rates. However, the meta- analysis 
also pointed out that, in general, antibiotics were not 
used uniformly in terms of regimens, timing, dosing, and 
duration.20
Lack of clear consensus and absence of universal guide-
lines regarding postoperative continuation of prophylaxis 
results in significant practitioner variation. In a study by 
Brahmbhatt et al,21 16% of practitioners reported that, 
most of the time, they use postoperative antibiotics as 
prophylaxis; in contrast, 76% responded that they never 
use postsurgical prophylaxis for more than 24 hours in 
patients without reconstruction. The length of prolonged, 
postoperative antibiotics may also vary by practitioners, 
some using a predefined regimen of about 2–7 days while 
others continue them until the drains are removed.
Rationale
There is no clear consensus regarding the continuation 
of postoperative antibiotic prophylaxis following breast 
surgeries, consequently significant practitioner variation 
exists globally. Various studies have failed to establish the 
impact of postoperative antibiotic prophylaxis on rates of 
SSIs, thus a prospectively designed phase III clinical trial 
is essential to provide higher level evidence. We propose 
to study the difference in rates of SSI in a double- blinded, 
multicentre trial by randomising patients undergoing 
mastectomy (without immediate reconstruction and with 
indwelling drains) to be randomised to either continuing 
prophylactic antibiotics or receiving a placebo postopera-
tively. All will receive a single dose of prophylactic antibi-
otic preoperatively.
Objectives
1. To determine the rates of SSI in patients in the two 
arms of this trial, in which all patients will receive the 
first prophylactic preoperative antibiotic dose at induc-
tion of anaesthesia and then be randomised to:
a. Receive a placebo every 8 hours, as long as there is/
are drains(s) in place.
b. Continue receiving prophylactic antibiotic every 8 
hours for the duration of indwelling drains.
2. To identify factors associated with differing rates of SSI 
in the intervention and control group.
Trial design
This is a two- armed, randomised, double- blinded placebo 
control clinical trial. The study participants will be 
women, 18 years and older, who are planned to undergo 
mastectomy without immediate reconstruction and will 
have indwelling closed suction drain(s). We used the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials checklist when writing this protocol.22
METHODS: PARTICIPANTS, INTERVENTIONS AND OUTCOME
Study setting
This study will be conducted at three sites:
Site 1: Aga Khan University Hospital (AKUH), Karachi, 
Pakistan, a tertiary care private hospital.
Site 2: Liaquat National Hospital (LNH), Karachi, Paki-
stan, a tertiary care private hospital.
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Site 3: DOW University of Health Sciences (DUHS), 
Karachi, Pakistan, a public sector hospital.
Eligibility criteria
Inclusion criteria: this trial will include all the patients 
who are:
 ► Women, 18 years and older, who are planned for 
mastectomy by a breast surgeon at one of the study 
sites, that is, AKUH, LNH or DUHS, and who will have 
indwelling closed suction drain(s) postoperatively.
 ► Women who will give consent to participate in the 
study.
Exclusion criteria: this study will exclude all those 
patients who will:
 ► Undergo immediate breast reconstruction. The 
healthcare payment model in the developing world, 
including Pakistan, is fee- for- service in which a 
patient pays for each individual medical care service, 
including reconstruction. Subsequently, reconstruc-
tion is an expensive procedure, which poses a huge 
financial burden for a majority of patients. Addition-
ally, locally advanced breast cancer is more prevalent 
in our setting than the developed world in the West, 
warranting postmastectomy radiation, which often 
leads us to recommend delayed reconstruction as the 
preferred option. Thus, most patients who undergo 
mastectomy either do not elect or are not ideal candi-
dates for immediate reconstruction.
 ► Have other medical indications for which they must 
remain on antibiotics for more than the single preop-
erative dose.
 ► Have any history of allergies to beta- lactam drugs or 
iodine.
 ► Had an open breast or axillary biopsy/breast conser-
vation in the last 30 days on the ipsilateral side.
Interventions: description, modifications and adherence
Description
Treatment arm
Standard care 1 g intravenous cefazolin given preopera-
tively at induction of anaesthesia followed by a course of 
500 mg oral cephalexin given every 8 hours for the dura-
tion of the indwelling drains.
Control arm
Standard care 1 g intravenous cefazolin given preopera-
tively at induction of anaesthesia followed by a course of 
oral placebo capsules (identical in physical appearance to 
the antibiotic) given every 8 hours for the duration of the 
indwelling drains.
The investigational product will be stored in the Clin-
ical Trial Unit (CTU) research pharmacy with controlled 
access under the direct supervision of the CTU pharma-
cist. The CTU pharmacist in the presence of the study 
team personnel will verify the expiry and lot/batch 
number at the time of receiving. The expiry date and the 
batch number will be documented in the pharmacy logs 
(investigational product/supplies inventory and expiry 
log). All unused investigational products collected from 
patients will be returned to the CTU pharmacy. The CTU 
pharmacist will also keep track of inventory and will notify 
the principal investigator and study coordinator when the 
investigational product (IP) needs to be restocked.
Study flow
Three research assistants, one for each site, are medical 
and dental graduates (with experience of facial wounds), 
who would be trained in the Centre for Disease Control 
(CDC) wound assessment criteria for SSIs by the prin-
ciple investigator (PI) and the co- PI (an infectious 
disease specialist) over a 2- week period prior to initiating 
the trial. Research assistants would also be required to 
shadow the PI in the clinics for a week to have uniform 
training regarding wound assessment, before initiation 
of the trial. Also, a research coordinator will liaise with 
the research assistants and will be coordinating the study 
at all three sites. The research coordinator will ensure 
an adequate supply of the study drug as well as placebo 
prepared by the AKUH pharmacy to be dispensed to the 
CTUs of respective institutions. At each of the three sites, 
a consistent approach to monitoring/documentation of 
SSI as well as adverse outcomes will be ensured by the 
research team.
All patients who are consented and booked for mastec-
tomy (without reconstruction) by the participating 
surgeons of AKUH, LNH and DUHS will be screened 
by trained research assistants during the outpatient 
preoperative clinic visit (online supplemental appendix 
1). The eligible and consented participants will then be 
randomised preoperatively by the CTU pharmacist (as 
above) using a computer- generated randomisation list, to 
either the intervention or control arm.
At the time of surgery, standardised skin preparation 
will be performed for both arms before the incision by 
the surgical team. The prep will consist of:
1. Povidone iodine 0.75 % W/V with normal saline hand 
scrub.
2. Iodine preparation paint.
3. Cefazolin 1 g intravenous preoperatively at the induc-
tion of anaesthesia.
Postsurgery
1. The intervention arm will be administered oral cef-
alexin 500 mg every 8 hours, which will be continued 
for the duration of the indwelling drains (usually 14 
days).
2. The control arm will be administered an identical in 
appearance placebo capsule filled with inert material 
for the duration of the drains.
3. All study medications, that is, antibiotic/placebo, will 
be dispensed by the CTU pharmacist.
Wound assessment
1. SSI will be assessed by the treating surgeon and the 
wound assessor (trained research assistants) during the 
follow- up visits. The research assistants will be doing 
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their independent wound assessment without being in-
fluenced by the surgeon. The data collection form has 
separate areas to document findings of surgeons as well 
as the wound assessor for independent evaluations.
2. The first postoperative visit will be on postoperative 
day 5±2 days (3–7 days) and subsequently at each rou-
tine postoperative visit while the drain is in place. As 
per CDC guidelines, the day of the procedure will be 
considered postoperative day 1. Rates of SSI will be 
collected up to the 90th postoperative day. If the pa-
tient does not have a routine clinic visit scheduled on 
day 90, the wound assessor (trained research assistant) 
will call the patient over the phone to inquire about 
the status of the wound. If need be, the patient will be 
asked to come in for a wound evaluation.
3. Rates of drug- related adverse effects will be 
documented.
Data will also be collected on the patient’s clinical 
factors potentially relevant to SSI, including smoking 
status (as never smoker, prior smoker and patients who 
quit smoking within the last 60 days before surgery), 
patient’s age, body mass index (BMI; >30 is defined as a 
marker of obesity) diabetes mellitus and recent corticos-
teroid use (inhaled/oral), prior ipsilateral breast/axillary 
surgery in the last 60 days, neoadjuvant chemotherapy, 
prior radiation to the ipsilateral breast and patients with 
active tuberculosis, HIV or on immunosuppression. Data 
will also be abstracted on the type of surgery performed 
defined as:
a. Unilateral/bilateral mastectomy.
b. Associated axillary surgery (none, sentinel lymph node 
biopsy, axillary sampling or axillary dissection).
c. The procedural length will be recorded in minutes 
from the start of incision to completion of skin closure.
d. Type of skin closure (staples vs subcuticular).
e. Duration of drain retention (counting day of surgery 
as day 1).
f. Duration of hospital stay, counting the day of admis-
sion as day 1.
g. Other constant variables will be additionally evaluat-
ed as dichotomous categorical variables, that include 
BMI >30, hospital stay >1 day, drain duration >14 days 
and having more than one drain in situ. Length of the 
stay >1 day is selected for comparison as most of our 
patients are discharged the day after the procedure at 
our institute. Age will be additionally evaluated cate-
gorically by decade (online supplemental appendix 2).
Modification
Discontinuation from the study
1. Any adverse effects as perceived (by the treating sur-
geon) to be related to the study drug. This includes, 
but is not limited to, rash and diarrhoea.
2. Development of a wound infection while on the study 
drug (the patient will exit the study and the infection 
will be treated and counted as the outcome).
3. Need for reoperation on the same site within 30 days 
of the mastectomy (except for when reoperation is for 
infection, in which case the patient will exit the study, 
but the infection will be counted as the outcome).
Adherence
Subject compliance will be monitored by the CTU phar-
macist, by counting the returned study drug/capsules as 
well as by reviewing the compliance log maintained by the 
patient. An additional compliance log will be maintained 
by the primary investigator/study team after a reminder 
telephone call to the participants in each group. This 
phone call will be made to reinforce the instructions and 
the need to maintain the log, as well as for reassurance. 
(online supplemental appendix 3).
Outcomes
Primary outcome: SSI (time frame: up to 90 days).
Standard CDC criteria:23
1. Purulent drainage from the incision or drain site.
2. Organisms isolated from an aseptically obtained cul-
ture of fluid or tissue.
3. Deliberate opening of the incision by a surgeon in pa-
tients having either tenderness, localised swelling, red-
ness or warmth.
4. Diagnosis of SSI by the surgeon or study wound asses-
sor.
5. Prescription of therapeutic antibiotics.
6. Patients clinically diagnosed and documented to have 
cellulitis.
Other outcome measures
Rates of antibiotic- associated side effects (time frame: will 
be assessed during the follow- up visits between postopera-
tive days 3 and 7 for the first postoperative visit and subse-
quently at each routine postoperative visit while the drain 
is in place, for a maximum of 90 days).
Participant timeline
Patients will be enrolled preoperatively, after consenting 
to the surgical procedure. Research assistants will screen/
consent the patient and liaise with the CTU to arrange 
for the relevant study drug. All study patients (in both 
arms) will receive the preoperative antibiotic prophylaxis 
at the time of induction. The postoperative antibiotic/
placebo doses will be administered to the patient at an 
interval of 8 hours and will continue for the duration 
of the indwelling drains. Patients will be followed for 90 
postoperative days, counting the day of the surgery as day 
1. At each follow- up visit, the patient will be assessed both 
by the primary surgeon/another covering study surgeon 
as well as the wound assessor (trained research assistant). 
Over the phone, follow- ups will be done by the wound 
assessor (trained research assistant) only.
Sample size calculation
The sample size was calculated in OpenEpi software 
V.3.01. The minimum sample size that will be required 
is 384 patients who have undergone mastectomy with 
indwelling drains. Of these, 192 patients will be those 
with a single dose of prophylactic preoperative antibiotic 
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and prolonged use of prophylactic postoperative oral 
antibiotics (intervention arm), and 192 participants will 
be those with a single dose of prophylactic preoperative 
antibiotic with placebo (control arm), with inflation of 
10% in both the groups for non- response rate. An antic-
ipated incidence of surgical site infection (SSI) of 3.4% 
in the intervention arm and 9.2%–14% in the control 
arm,4 24 with a 5% level of significance and power of 80% 
to detect a 9% reduction of infection in intervention arm 
versus the control. Since we will be recruiting participants 
from three study sites, we applied proportionate sampling 
to estimate the sample size for each group. In this tech-
nique, the sample size of each site is proportionate to 
the total population size, which was 565. We calculated 
the per cent (weight) for each group by taking a ratio of 
the number of individuals in each group and the total 
population. Hence, we will require a minimum sample 
of 66 women in the intervention arm and 66 women in 
the control arm from AKU, 85 women in the intervention 
arm and 85 women in the control arm from LNH, and 41 
women in the intervention arm and 41 women in control 
arm from DUHS campus.
METHODS: ASSIGNMENT OF INTERVENTIONS (CONTROLLED 
TRIAL)
Allocation: sequence generation, concealment mechanism 
and implementation
The PI’s research fellow will serve as the research coor-
dinator and will be responsible for coordination with 
the specially hired and trained wound assessors/trained 
research assistants. At each of the three study sites, the 
research assistants will be responsible for recruiting 
participants, obtaining the study drug from the CTU 
and delivering it to the patient, giving instructions and 
following up on the wound status as well as for study drug 
compliance. The research assistants will receive adequate 
training from the principal investigator.
Randomisation will be performed by the block rando-
misation method. Patients will be allocated to one of the 
following groups:
Group 1 (intervention arm): will be those patients who 
will receive a single dose of prophylactic preoperative 
antibiotic (cefazolin 1 g intravenously preoperatively), 
then continue with oral cefalexin (capsule) 500 mg every 
8 hours, for the duration of the drains, which usually is 
about 14 days.
Group 2 (control arm): will be those who receive a single 
dose of prophylactic preoperative antibiotic (cefazolin 1 
g intravenously preoperatively). Postoperatively, these 
patients will receive a capsule filled with inert material 
every 8 hours (placebo capsule, which will be identical in 
appearance to the study antibiotic).
Randomisation will be performed via computer- 
generated random numbers by the AKUH CTU 
pharmacy.
Blinding (masking)
This study is a double- blinded randomised controlled 
trial as our participants and the treating surgeon/wound 
assessor (trained research assistant) will be blinded to 
the group that each participant will be assigned to. As an 
additional measure to maintain blinding, both the study 
antibiotic and placebo will be dispensed by the CTU in 
capsules that have an identical appearance.
Blinding (masking): emergency unblinding
Unblinding can be done in the following situations:
1. Accidental unblinding.
2. Unblinding due to any serious adverse event (SAE).
In either case, the principal investigator will promptly 
document and explain any unblinding to the sponsor and 
the Ethics Review Committee (ERC). If a patient’s treat-
ment assignment is unblinded, the patient will remain in 
the study and continue the protocol- specified follow- up 
evaluations.
METHODS: DATA COLLECTION, MANAGEMENT AND ANALYSIS
Data collection plan
The outcome assessment (SSI) will be performed by 
the treating surgeon and the wound assessor (trained 
research assistant) during the follow- up visits. The data 
on the patient’s demographics and other disease- related 
information will be collected on a structured question-
naire. The data collection form can be made available 
from the corresponding author on reasonable request.
Data collection plan: retention
All this information will be maintained at the CTU AKUH.
Data management
The data will be entered in Redcap software. The data 
will be double entered and range checks will be entered 
to maintain the quality of the data. The database is autho-
rised only to the principal investigator. The database can 
be made available from the corresponding author on 
reasonable request.
Statistics: analysis population and missing data
We plan to do the intention- to- treat analysis as mentioned 
in the plan of analysis. The missing data will be dealt with 
by imputation. The analysis will be performed using 
STATA V.12. Descriptive statistics will be computed for 
categorical variables by computing their frequencies 
and percentages and will be assessed by χ2 test/Fisher’s 
exact test as appropriate. The quantitative variables will 
be computed by their mean±SD or median (IQR) and 
will be assessed by independent t- test/Mann- Whitney 
test as appropriate. Unadjusted and adjusted relative risk 
with their 95% CI will be reported by using Cox propor-
tional regression. All plausible interactions will also be 
assessed. Intention- to- treat analysis will be carried out. A 
p value of <0.05 will be considered statistically significant 
throughout the study.
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METHODS: MONITORING
Data monitoring: formal committee
The data monitoring team of AKUH CTU (principal site) 
will overlook the trial. This data monitoring committee 
overlooks all the trials that take place at the Aga Khan 
University and is independent of the sponsors. Further 
details of its key services and ancillary services can be 
found online (https://www. aku. edu/ ctu/ services/ 
Pages/ home. aspx).
Data monitoring: interim analysis
The data and safety monitoring committee, composed of 
an independent group of experts in the involved fields 
(biostatistician, clinical researcher, epidemiologist and 
a clinician with expertise in the disease under investi-
gation), will conduct an interim analysis. If significantly 
high rates of SSI in one group compared with the other 
at interim analysis is observed, the trial will be stopped.
Harms
Adverse events
In the event of an adverse effect, study participants will be 
instructed to report to their treating surgeon immediately. 
The primary surgeon will then assess if the symptoms are 
an adverse drug effect and recommend withdrawal from 
the study if deemed so. The anticipated drug adverse 
could be events, such as a drug allergy, Clostridium difficile 
or antibiotic- associated diarrhoea. Only <5% of patients 
develop allergy due to cephalosporin use; similarly, there 
is inconsistency regarding the relationship of C. difficille- 
associated diarrhoea with cephalosporin use.25–27 Investi-
gations pertaining to the adverse drug effect may include, 
but are not limited to, complete blood counts and stool 
test (for suspected C. difficille). The adverse events (AEs) 
will be recorded and reported to ERC within a specified 
period. A patient thought to have an adverse reaction 
will exit the trial at this point. Management given for the 
AE/SAE will be documented in the study documents. 
All drug accountability will be maintained in the CTU. 
If the patient is withdrawn from the study, they will be 
encouraged to complete the follow- up visits and data will 
be collected for the follow- up visit.
Assessment of safety
Any untoward medical occurrence in a patient or clin-
ical investigation subject administered a pharmaceutical 
product and which does not necessarily have a causal rela-
tionship with this treatment will also be documented. An 
AE can, therefore, be any unfavourable and unintended 
sign (including an abnormal laboratory finding), symptom 
or disease temporally associated with the use of a medic-
inal (investigational) product, whether or not related to 
the medicinal (investigational) product. All study- related 
adverse/serious AEs will be managed and reported to the 
ERC, medical affairs and pharmacy. The principal investi-
gator and study coordinator will follow- up on any AEs and 
SAEs. The type and duration of the follow- up of subjects 
after AEs will be defined by the PI.
Reporting and recording of procedures of adverse events
The PI will report all AEs in case report form (CRF)/
Data Clarification form (DCF), AE reporting form to 
the sponsor (in the specified time) and to the ERC. 
SAE will be reported to the sponsor via telephone, 
email, and/or fax within 24 hours. Confirmation will be 
ensured and documented. The immediate report will 
be followed by a detailed written report on the event 
and SAE/AE form along with supporting documents 
will be submitted to the study sponsor and ERC no later 
than 7 days from notification of the event. The PI will 
also report to relevant authorities within 15 calendar 
days after SAE/unanticipated AE that may be related to 
the study protocol. The PI will also be responsible for 
reporting all serious or unexpected AE to ERC within 7 
days from notification of the event. Requests from the 
sponsor/ERC for further information of the SAE will be 
promptly responded to.
Patients will be withdrawn from the study due to:
1. Withdrawal of consent by the patient or legal guardian.
2. Development of any AE or SAE.
3. Investigator decision that, in the interest of the patient, 
it is not medically acceptable to continue the patient’s 
participation in the study.
4. Termination of the study by the sponsor.
If the patient withdraws from the study, the principal 
investigator will promptly document and inform the 
sponsor about the termination from the study within 48 
hours. Despite withdrawing from the study, patients will 
be encouraged to complete the follow- up visits and data 
will be collected for the follow- up visit. Participants who 
will withdraw or will be terminated from the study will not 
be replaced as the sample size is calculated keeping in 
view the 10% non- response rate.
Auditing
The audit of the trial is usually conducted by the ERC 
(and sometimes by Joint Commission International) who 
are independent from the investigators and the sponsors.
Ethics and dissemination
Research ethics approval
Ethical approval has been obtained from the ERC of all 
three study sites that is, the Aga Khan University, Kara-
chi’s ERC, and ERC at LNH and DUHS. The study will be 
conducted according to the Consolidated Standards of 
Reporting Trials guidelines (figure 1) and guidelines of 
the World Medical Association’s Declaration of Helsinki 
and the principles of Good Clinical Practice (GCP). 
The study background and procedure will be explained 
to the study participants and informed consent will be 
obtained. Participation in the study is voluntary. All 
data will be deidentified and will be kept confidential. 
The study findings will be published in the scientific 
media and the authorship guidelines of International 
Committee of Medical Journal Editors (ICMJE) will be 
followed.
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Protocol amendments
Any amendment in protocol will be submitted to the ERC 
and regulatory authorities for approval, and the trial will 
be conducted in compliance with regulations reporting, 
6- month/annual safety and progress reports, and a copy 
of the final study report will be submitted to the ERC and 
funding agency.
Consent or assent
Participants will be recruited from AKUH, LNH and 
DUHS. Written informed consent will be obtained from 
the participants by trained research assistants/data 
collectors (online supplemental appendix 4). They will 
be explaining the study procedure in detail to the study 
participants along with the risks and benefits associated 
with taking part in the study. The data collectors will be 
trained by the PI and co- investigators. Randomisation for 
all study sites will take place at the CTU AKUH.
Confidentiality
Strict confidentiality and privacy rules will be followed. 
Patients will be informed that all information will be kept 
confidential. All study materials containing personal iden-
tifiers will be kept in a locked file cabinet. A unique study 
identification number will be assigned to each partici-
pant. Data will be entered from the hard copy into the 
electronic database that will be password protected and 
only accessed by the research staff of this study. As per 
GCP guidelines, data will be retained for 15 years. The 
participation of the participants will be voluntary.
Data access
The principal investigator and other authors of the study 
will have access to the final data set.
Ancillary and post-trial care
The cost of all the AEs will be borne by the study budget.
Dissemination policy: trial results
The study findings will be disseminated to different 
stakeholders, such as healthcare professionals through 
publications in local, national and international journals, 
presentations at conferences and workshops, and research 
briefs.
Dissemination policy: authorship
We will follow the authorship guidelines of ICMJE for 
authorship eligibility. At the moment, we do not intend 
to use any professional writers. However, if the journal 
suggests reaching out to English proofreading experts, 
we will seek professional assistance.
Dissemination policy: reproducible research
Materials that are described in this manuscript pertain to 
the study protocol and no raw data is being reported. The 
data set will be collected and analysed and can be made 
available from the corresponding author on reasonable 
request.
Patient and public involvement
It was not possible to involve patients or the public in the 
design, or conduct, or reporting, or dissemination plans 
of our research.
Strengths and limitations of the study
First, this will be a multicentre study, including both public 
and private tertiary care hospitals catering to patients 
from different socioeconomic backgrounds. Hence, 
our study results will be generalisable to all mastectomy 
patients who have drains in place and have not under-
gone reconstruction. Moreover, to the best of our knowl-
edge, this will be the first study from our context. Finally, 
the pragmatic approach will allow easy applicability to the 
current practice of individuals across a wide range of clin-
ical settings. One of the limitations of our study is that 
patients with reconstruction will be excluded to prevent 
variability in outcomes.
Study implications
Through this study, we will be able to identify the most 
effective prophylactic regimen to reduce rates of SSI 
among mastectomy patients with indwelling drains, hence 
it will lead to informed decision- making. The results will 
be widely generalisable and applicable worldwide.
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Assessed for eligibility 
(n = …) Excluded (n = … 
- Not meeting inclusion 
criteria (n = …) 
- Refused to participate (n = 
…) 
- Other reason (n = …) 
Randomized (n = ….) 
Allocated to intervention arm (n =) 
Received allocated intervention (n =) 
Did not receive allocated intervention 
(give reasons) (n = …) 
Lost to follow-up (give 
reason) (n = …) 
Discontinued intervention 
(give reasons) (n = …) 
 
Allocated to control arm (n =)  
Received allocated treatment (n =) 
Did not receive allocated treatment 
(give reasons) (n = …) 
Lost to follow-up (give 
reason) (n = …) 
Discontinued intervention 
(give reasons) (n = …) 
 
Analyzed (n = …) 
Excluded from analysis (give 
reasons) (n = …) 
Analyzed (n = …) 
Excluded from analysis (give 
reasons) (n = …) 
Figure 1 Consolidated Standards of Reporting Trials 2010 
flow diagram.
 on A












pen: first published as 10.1136/bm




8 Sattar AK, et al. BMJ Open 2021;11:e049572. doi:10.1136/bmjopen-2021-049572
Open access 
Competing interests There is no financial or competing interest for the principal 
investigator for the overall trial and each study site.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer- reviewed.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Abida K Sattar http:// orcid. org/ 0000- 0002- 9836- 7825
Nida Zahid http:// orcid. org/ 0000- 0001- 8812- 9463
Hania Shahzad http:// orcid. org/ 0000- 0002- 1643- 0828
REFERENCES
 1 Zeeshan S, Ali B, Ahmad K, et al. Clinicopathological features of 
young versus older patients with breast cancer at a single Pakistani 
institution and a comparison with a national us database. J Glob 
Oncol 2019;5:1–6.
 2 Vilar- Compte D, Jacquemin B, Robles- Vidal C, et al. Surgical site 
infections in breast surgery: case- control study. World J Surg 
2004;28:242–6.
 3 Throckmorton AD, Hoskin T, Boostrom SY, et al. Complications 
associated with postoperative antibiotic prophylaxis after breast 
surgery. Am J Surg 2009;198:553–6.
 4 Degnim AC, Scow JS, Hoskin TL, et al. Randomized controlled trial 
to reduce bacterial colonization of surgical drains after breast and 
axillary operations. Ann Surg 2013;258:240–7.
 5 Angarita FA, Acuna SA, Torregrosa L, et al. Perioperative variables 
associated with surgical site infection in breast cancer surgery. J 
Hosp Infect 2011;79:328–32.
 6 Seo SK. An updated meta- analysis on the effectiveness of 
preoperative prophylactic antibiotics in patients undergoing breast 
surgical procedures. Breast Diseases: A Year Book Quarterly 
2013;24:161–2.
 7 Cochrane LibraryJones DJ. Prophylactic antibiotics to prevent 
surgical site infection after breast cancer surgery, 2014. Available: 
https://www. cochranelibrary. com/ cdsr/ doi/ 10. 1002/ 14651858. 
CD005360. pub4/ full
 8 Specifications manual for joint commission national quality core 
measures [Version B1, July 2010] https://www. jointcommission. 
org/-/ media/ tjc/ documents/ resources/ hai/ implementation_ guide_ for_ 
npsg_ ssipdf. pdf
 9 Felippe WAB, Werneck GL, Santoro- Lopes G. Surgical site infection 
among women discharged with a drain in situ after breast cancer 
surgery. World J Surg 2007;31:2293–9.
 10 Gao Y- xu, Xu L, Ye J- ming, et al. Analysis of risk factors of surgical 
site infections in breast cancer. Chin Med J 2010;123:559–62.
 11 Vilar- Compte D, Rosales S, Hernandez- Mello N, et al. Surveillance, 
control, and prevention of surgical site infections in breast cancer 
surgery: a 5- year experience. Am J Infect Control 2009;37:674–9.
 12 Teija- Kaisa A, Eija M, Marja S, et al. Risk factors for surgical site 
infection in breast surgery. J Clin Nurs 2013;22:948–57.
 13 Thomson DR, Sadideen H, Furniss D. Wound drainage after axillary 
dissection for carcinoma of the breast. Cochrane Database Syst Rev 
2013;10:CD006823.
 14 Rotstein C, Ferguson R, Cummings KM, et al. Determinants of clean 
surgical wound infections for breast procedures at an oncology 
center. Infect Control Hosp Epidemiol 1992;13:207–14.
 15 Rey JE, Gardner SM, Cushing RD. Determinants of surgical site 
infection after breast biopsy. Am J Infect Control 2005;33:126–9.
 16 Throckmorton AD, Boughey JC, Boostrom SY, et al. Postoperative 
prophylactic antibiotics and surgical site infection rates in breast 
surgery patients. Ann Surg Oncol 2009;16:2464–9.
 17 Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice 
guidelines for antimicrobial prophylaxis in surgery. Surg Infect 
2013;14:73–156.
 18 Hedrick TL, Smith PW, Gazoni LM, et al. The appropriate use of 
antibiotics in surgery: a review of surgical infections. Curr Probl Surg 
2007;44:635–75.
 19 Consensus guideline on preoperative antibiotics and surgical site 
infection in breast surgery;6 https://www. breastsurgeons. org/ docs/ 
statements/ Consensus- Guideline- on- Preoperative- Antibiotics- and- 
Surgical- Site- Infection- in- Breast- Surgery. pdf
 20 Hai Y, Chong W, Lazar MA. Extended prophylactic antibiotics for 
mastectomy with immediate breast reconstruction: a meta- analysis. 
Plast Reconstr Surg Glob Open 2020;8:e2613.
 21 Brahmbhatt RD, Huebner M, Scow JS, et al. National practice 
patterns in preoperative and postoperative antibiotic prophylaxis in 
breast procedures requiring drains: survey of the American Society of 
breast surgeons. Ann Surg Oncol 2012;19:3205–11.
 22 Chan A- W, Tetzlaff JM, Gøtzsche PC, et al. Spirit 2013 explanation 
and elaboration: guidance for protocols of clinical trials. BMJ 
2013;346:e7586.
 23 Control CfD, Prevention. Surgical site infection event SSIS. 
Guidelines and procedures for monitoring SSI. 2014 - Google 
Search, 2021. Available: https://www. cdc. gov/ nhsn/ pdfs/ pscmanual/ 
9pscssicurrent. pdf
 24 Edwards BL, Stukenborg GJ, Brenin DR, et al. Use of prophylactic 
postoperative antibiotics during surgical drain presence following 
mastectomy. Ann Surg Oncol 2014;21:3249–55.
 25 Wilcox MH, Mooney L, Bendall R, et al. A case- control study of 
community- associated Clostridium difficile infection. J Antimicrob 
Chemother 2008;62:388–96.
 26 Wilcox MH, Chalmers JD, Nord CE, et al. Role of cephalosporins 
in the era of Clostridium difficile infection. J Antimicrob Chemother 
2017;72:1–18.
 27 Thomas C, Stevenson M, Riley TV. Antibiotics and hospital- acquired 
Clostridium difficile- associated diarrhoea: a systematic review. J 
Antimicrob Chemother 2003;51:1339–50.
 on A












pen: first published as 10.1136/bm
jopen-2021-049572 on 9 July 2021. D
ow
nloaded from
 
